Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Dementia of the Alzheimer TypeAge-related Cognitive DeclineMild Cognitive Impairment Due to Alzheimer Disease
Interventions
DRUG

Probucol

"Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US."

Trial Locations (1)

H4H1R3

Douglas Hospital Research Centre, Montreal

All Listed Sponsors
collaborator

Weston Brain Institute

OTHER

collaborator

McGill University

OTHER

lead

Douglas Mental Health University Institute

OTHER

NCT02707458 - Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration | Biotech Hunter | Biotech Hunter